Israel's MediWound beats Q2 revenue estimates, reaffirms 2026 guidance
MDWD•Outlook
- MediWound reaffirms 2026 revenue guidance of $24–26 mln
- Company expects to begin recognizing revenue from Vericel agreement in H2 2026
- Commercial supply from expanded NexoBrid facility expected in H2 2027, pending approval
Overview
- Israel biotech's Q2 revenue fell but beat analyst expectations
- Gross profit margin declined due to one-time facility scale-up impact
- Company reaffirmed full-year 2026 revenue guidance of $24–26 mln
Result Drivers
- BARDA revenue timing - Co said lower Q2 revenue and gross profit reflected timing of BARDA-funded development revenue
- R&D investment - Increased research and development expenses were driven by investment in EscharEx Phase III VALUE trial
- NexoBrid adoption - Vericel reported record quarterly revenue and hospital unit sales for NexoBrid, reflecting continued adoption in U.S. burn care market
Key details and analyst coverage
| Metric | Beat/Miss |
|---|
